GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Excerpt from the article:
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy.
“GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional responders to COVID-19. There’s never been anything like that before,” “We’re establishing a completely new type of drug.”
GigaGen CEO and co-founder David Johnson, Ph.D., told BioSpace.
Click the button below to read the Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?